Title: Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse

Population in the United States

Authors: Kaitlin Rainwater-Lovett[1,2], John T. Redd[2], Miles A. Stewart[1,2], Natalia Elías Calles[3], Tyler

Cuff[3], Mike Fang[1], Mark J. Panaggio[1], Anastasia S. Lambrou[1,2], Jonathan K. Thornhill[1,2], Christopher

Bradburne[1,4], Samuel Imbriale[2], Jeffrey D. Freeman[1,2], Michael Anderson[2], Robert Kadlec[2]

Affiliations: [1]Asymmetric Operations Sector, Johns Hopkins University Applied Physics Laboratory,

Laurel, Maryland; [2]Office of the Assistant Secretary for Preparedness and Response, U.S. Department of

Health and Human Services, Washington, DC; [3]Tucson Medical Center, TMC HealthCare, Tucson,

Arizona; [4]McKusick-Nathans Department of Genetic Medicine, Johns Hopkins School of Medicine,

Baltimore, Maryland.

Keywords: Monoclonal antibody; bamlanivimab; SARS-CoV-2; COVID-19; emergency response

Running Title: Monoclonal Antibodies in COVID Patients

Corresponding Author: Kaitlin Rainwater-Lovett, PhD, MPH; Kaitlin.Lovett@jhuapl.edu

Alternate Corresponding Author: John T. Redd, MD, MPH; John.Redd@hhs.gov

Summary: In a diverse, real-world COVID-19 patient population, treatment with monoclonal antibodies

significantly decreased the risk of subsequent emergency department visit or hospitalization within 30

days of a positive SARS-CoV-2 viral test.

ABSTRACT

Background: Monoclonal antibodies (mAbs) against SARS-CoV-2 are a promising treatment for limiting the progression of COVID-19 and decreasing strain on hospitals. Their use, however, remains limited, particularly in disadvantaged populations.

Methods: Electronic health records were reviewed from SARS-CoV-2 patients at a single medical center in the United States that initiated mAb infusions in January 2021 with the support of the U.S. Department of Health and Human Services' National Disaster Medical System. Patients who received mAbs were compared to untreated patients from the time period before mAb availability who met eligibility criteria for mAb treatment. We used logistic regression to measure the effect of mAb treatment on the risk of hospitalization or emergency department (E.D.) visit within 30 days of laboratory-confirmed COVID-19.

Results: Of 598 COVID-19 patients, 270 (45%) received bamlanivimab and 328 (55%) were untreated. Two hundred and thirty-one patients (39%) were Hispanic. Among treated patients, 5/270 (1.9%) presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test, compared to 39/328 (12%) untreated patients ($p<0.001$). After adjusting for age, gender, and comorbidities, the risk of E.D. visit or hospitalization was 82% lower in mAb-treated patients compared to untreated patients (95% confidence interval [CI]: 66%-94%).

Conclusions: In this diverse, real-world COVID-19 patient population, mAb treatment significantly decreased the risk of subsequent E.D. visit or hospitalization. Broader treatment with mAbs, including in disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all populations in the United States to ensure health equity.

BACKGROUND

In late 2019, a new respiratory infection was detected in China and alarmed global health experts with its growing case incidence and clinical severity [1,2]. Over the course of a few months, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) spread around the world, overwhelming health systems. While a substantial proportion of patients remain asymptomatic [3], coronavirus disease 2019 (COVID-19) can rapidly progress and require hospitalization and intensive care. Severe disease is associated with older age, obesity, and several chronic medical conditions including cardiovascular, kidney, and pulmonary comorbidities [4–7].

As of late January 2021, approximately 15,000 new COVID-19 hospital admissions were occurring per day in the United States (U.S.) and hospital bed capacity exceeded 72% [8,9]. As healthcare systems continued to approach maximum bed capacity, a critical need for therapeutic interventions to reduce COVID-related hospitalizations emerged. Although therapeutic options for COVID-19 remain limited, monoclonal antibodies (mAbs) that neutralize SARS-CoV-2 are a promising treatment for limiting the progression of disease. Four mAbs are available in the U.S. through Emergency Use Authorizations (EUAs) by the U.S. Food and Drug Administration (FDA): bamlanivimab monotherapy [10], bamlanivimab in combination with etesevimab [11], and casirivimab in combination with imdevimab [12]. These products are human IgG1 antibodies that neutralize the virus by binding the spike protein of SARS-CoV-2, preventing attachment of the virus to the human cellular receptor angiotensin-converting enzyme-2. A single infusion of bamlanivimab was recently demonstrated to reduce the risk of hospitalization, emergency department (E.D.) visits, and death among patients with mild to moderate COVID symptoms in randomized, controlled phase 2/3 trials by more than 70% [10].

Monoclonal antibodies are underutilized as a treatment for reducing severe disease and could significantly decrease hospitalizations and potentially long-term COVID effects [13]. Utilization can be particularly challenging in minority, disadvantaged populations, in whom prevalence of risk factors for COVID-19

progression and death may be higher [14]. Thus, mAb may be particularly underutilized in precisely the

populations that would have the greatest benefit, threatening to exacerbate existing health inequities in the

United States. Two primary barriers to implementation of mAb infusion therapy are: 1) a limited

understanding of the necessary resources and processes to mobilize infusion sites, and 2) understanding

the magnitude of the potential impact of mAb treatment on reducing the severity of disease. We

previously addressed the first barrier through a process assessment and improvement analysis [15],

demonstrating considerable flexibility in assembling an infusion site and the feasibility of mAb delivery

in diverse treatment locations. Here, we aim to determine the extent to which mAb treatment decreases

COVID-related hospital admission and E.D. visits among patients with mild to moderate COVID-19

within 30 days of treatment in the U.S..

METHODS

We conducted a retrospective cohort study in February 2021 of SARS-CoV-2-positive patients to

evaluate the effect of mAb treatment on the risk of a medical visit within 30 days. This study evaluated

patients who presented to a single medical center to which the U.S. Department of Health and Human

Services' Assistant Secretary for Preparedness and Response (ASPR) had deployed elements of the

National Disaster Medical System (NDMS) to establish a mAb infusion site. This medical center is

located in a moderately sized city with a population of approximately 500,000. The city's population is

56.4% non-White with a median household income that is 64% of the U.S. level and a poverty rate of

23.4% [16,17]. This clinical support activity was conducted as part of the ASPR public health response to

the COVID-19 pandemic and at the request of the host medical center. Under HHS Office of Health

Research Protection guidelines, it was judged a non-research COVID-19 response [18]. The Johns

Hopkins University Applied Physics Laboratory and the medical center concurred with a non-research

determination.

The target population for this evaluation was patients with positive results of SARS-CoV-2 viral testing

who were 12 years of age or older, at least 40 kg in weight, and at high risk for progressing to severe

COVID-19 or hospitalization. Clinical data were obtained in February 2021 from electronic health

records maintained by the medical system, which includes both a major medical center and several

outpatient clinics with integrated health records.

Our retrospective cohort consisted of patients presenting to either outpatient clinics or the medical center

who tested positive for SARS-CoV-2 via an antigen or polymerase chain reaction-based test. Patients

with positive viral test results recorded in the electronic health record between July 1st and December 20th,

2020 were identified as untreated patients. These patients were eligible for inclusion in the analysis if they

met the eligibility criteria for mAb treatment (Table 1). Treatment with mAb became available at the

medical center on January 7th, 2021. SARS-CoV-2 patients who received mAb infusions between

January 7th and January 15th, 2021, are referred to as treated patients. We selected the test date of

December 20th, 2020, as the final date of eligibility for untreated patients to ensure no overlap in the

treated and untreated patient populations based on the maximum ten-day symptom onset window

permitting mAb treatment eligibility and decreased healthcare seeking behavior during winter holidays

[19]. The decision to seek mAb treatment for COVID-19 was made by the patient and the provider. At

presentation for mAb treatment, the date of SARS-CoV-2 test positivity was confirmed through paper

records provided by the patient or rapid antigen test performed on-site, and intake staff collected

demographic and clinical information, including eligibility criteria for treatment (Table 1). Any adverse

events were recorded on patient forms. While mAb treatments continued after January 15th, the end date

was established to permit sufficient follow-up at the time of data collection.

Data extracted from existing medical records included age, sex, race, ethnicity, height and weight, and

presence of the following pre-existing conditions as recorded by clinicians in the health record: blood

disorders (e.g., sickle cell disease, thalassemia), cancer, diabetes, Down syndrome, chronic lung disease,

chronic liver disease, hypertension, immunosuppressive condition, chronic kidney disease, obesity or

overweight, and organ transplant. Pre-existing conditions were captured from the Chief Complaint of

health records within the six months prior to the date of SARS-CoV-2 testing. Laboratory values and

clinical exam measurements were not extracted to define pre-existing conditions.

Race categories were defined as American Indian/Alaskan Native, Asian, Black, Hawaiian/Pacific

Islander, White, and other. Ethnicity was defined as Hispanic or Non-Hispanic. Body mass index (BMI)

was calculated as kilograms per meter-squared. In the absence of height and weight, the pre-existing

conditions of "obesity" and "overweight" were used for BMI categorization. The composite outcome of a

medical visit was defined as the first instance of COVID-19-related E.D. visit or hospitalization after

positive SARS-CoV-2 viral test result and was obtained from the electronic health record. A medical visit

was COVID-related if one or more of the following chief complaints were identified: blood in sputum,

chest congestion, chest pain, cough, COVID-19 screening, difficulty breathing, fever, flu-like symptoms,

hypoxia, shortness of breath, sore throat, or weakness [20–23]. Dates of COVID-19 symptom onset and

positive SARS-CoV-2 antigen test results performed at the infusion center were recorded on paper-based

forms upon arrival of patients for mAb treatment, but were not recorded in electronic health records.

Characteristics of patients were compared using Welch t-tests for continuous variables and Chi-squared

test for categorical variables. Age was categorized as younger than or equal to 65 years of age or older

than 65 years. Logistic regression was used to evaluate the effect of mAb treatment on medical visits that

occurred within 30 days of SARS-CoV-2-positive viral test by applying a generalized linear model with a

logits link function. The occurrence of a medical visit was evaluated as a binary outcome. Variables

included in the model were those deemed epidemiologically relevant. Model diagnostics indicated that no

data points substantially influenced model estimates, as assessed by Cook's distance. All data processing

and analyses were conducted using R version 4.0.3 [24].

RESULTS

Medical records were available from 875 SARS-CoV-2-positive patients (Figure 1) confirmed during July 1 through December 20, 2020. Of these, 547 patients did not meet eligibility criteria for mAb treatment (Figure 1). This resulted in the analysis of 598 patients, 270 of whom (45%) were eligible for and received bamlanivimab during a single week in January 2021, comprising the treated group. A total of 328 untreated patients (55%) served as the historical comparator population. These untreated patients represented individuals who would have been eligible for mAb infusion had the treatment been available at the time of their COVID-19-positive viral test results.

Among the 598 patients, no statistically significant differences in sex or ethnicity were identified between the treated and untreated study groups (Table 2). Untreated patients were an average of three years younger than the treated patients (p=0.02), and health records were more likely to report untreated patients as overweight or obese and with a history of hypertension or cardiovascular disease (all p<0.001).

In the 30 days following a positive SARS-CoV-2 test result, five of 270 treated patients (1.9%) presented to the E.D. or required hospitalization within 30 days of a positive SARS-CoV-2 test result, compared to 39 of the 328 untreated patients (12%) (p<0.01) (Table 2). Untreated patients had a medical visit a median of four days after SARS-CoV-2-positive viral test result (interquartile range [IQR]: 2, 8 days), while treated patients had a medical visit an average of eight days after mAb treatment (IQR: 4, 8) (p=0.112 by Kolmogorov-Smirnov test). No adverse events were reported among mAb-infused patients.

Treatment with mAb was associated with an 82% decrease in the risk of a COVID-19-related medical visit within 30 days of a positive SARS-CoV-2 viral test after adjusting for demographic factors and pre-existing conditions (95% CI: 66%, 94%) (Table 3). A BMI $\geq$ 35 greatly increased the risk of a medical visit in the multivariable analysis (odds ratio: 6.44 [95% CI: 2.48, 16.71]). Age $\geq$ 65 was also associated with a 2.10-fold increased risk but this was not statistically significant (95% CI: 0.97, 4.77).

DISCUSSION

This study demonstrated that a single infusion of bamlanivimab within 10 days of COVID-19 symptom

onset decreased the risk of COVID-related hospitalization and E.D. visits among a real-world, diverse

patient population in the U.S. who were at risk of progression to severe disease compared with an

historical untreated population. The association between treatment and improved clinical outcome

remained significant after controlling for gender, age, race, ethnicity, and pre-existing conditions. A BMI

of greater than 35 remained highly associated with disease progression requiring a medical visit after

adjusting for mAb treatment and other co-factors.

Approximately 2% of the treated group were hospitalized or visited the E.D. after mAb infusion, which

was similar to the rate of medical visits in the efficacy assessment of bamlanivimab [10]. In contrast,

almost 12% of untreated patients in the current study required a medical visit within 30 days of a positive

COVID test. This risk was nearly double the 6.3% of placebo controls who presented to the E.D., required

hospitalization, or died in the Phase 2/3 trial [10], suggesting that the current study's patient population

was older and had a higher risk of progression to severe disease. This difference reinforces the need to

evaluate therapeutics in diverse populations and in real-world clinical situations, as patients who are

referred for and receive treatments often differ from those who are enrolled in a clinical trial.

Few treatment options have been available during the COVID-19 pandemic for reducing the severity of

disease and preventing hospitalization, leading to significant strain on many hospitals[8]. Reducing the

proportion of patients who progress to severe disease and require hospitalization by approximately 80%

would be of immense value to medical centers, in which intensive care units contain an average of only

15 staffed beds [25]. The availability of mAbs at no drug cost due to their procurement by the U.S.

government places a therapeutic option more easily within reach of many who are at the highest risk of

severe disease.

The use of electronic health records is a strength of the current study. Due to the medical center's

electronic record system, we were able to assemble a SARS-CoV-2-positive cohort who would have been

eligible for mAb treatment at the time of their diagnosis based on pre-existing risk factors, had the

therapeutics been available at that time. An additional strength of this study was the diverse patient

population in the area, resulting in the inclusion of a large proportion of patients of Hispanic ethnicity

(39%). Our results are consistent with prior clinical trial data showing a 70% reduction in medical visits

by mAb-infused patients compared to placebo controls[10]. A BMI of 35 or higher was a strong

independent predictor of an increased risk of medical visits, which was consistent with other COVID-19

studies [7].

A significantly larger proportion of untreated patients had co-morbidities that increase the risk of severe

COVID-19 outcomes compared to treated patients in the current study, notably a higher proportion with

elevated BMI. Although mAb treatment remained significantly associated with a decreased risk of

hospitalization or E.D. visit after adjusting for pre-existing conditions (82% reduction; 95% CI: 66%,

94%), the baseline differences between the treated and untreated groups suggest a potential difference in

accessibility of mAb treatment. For example, patients with fewer co-morbidities may have more easily

been able to avail themselves of treatment. The continued U.S. government efforts to increase access to

mAbs are intended to ensure that COVID-19 therapeutics are equally available to all patients - an

important national health equity consideration.

To receive mAb infusions, patients must seek out treatment within 10 days of a positive SARS-CoV-2

antigen test result. This can be burdensome and stresses the importance of widespread availability of

testing. Evidence also suggests that patients with more significant or severe co-morbidities are likely to

have more complete health records [26,27]. This effect may have overrepresented patients with more

severe chronic conditions into the untreated group based on the application of mAb eligibility criteria for

inclusion in the analysis. Additionally, without active follow-up of patient outcomes, misclassification of

the medical visit outcome was possible as patients could seek follow-up care at any facility. These

considerations and the differences between the study groups suggest confounders remain that were

unmeasured in this analysis. These limitations could be further evaluated in a larger, prospective,

observational study.

While individuals at increased risk of SARS-CoV-2 infection and severe disease are prioritized for

vaccination in most U.S. states, therapeutic options such as mAb infusions remain a necessity for those

who remain unvaccinated due to contraindications or vaccine hesitancy [28,29]. Although viral variants

are being discovered that are poorly neutralized by several mAbs in laboratory studies [30,31], suggesting

reduced effectiveness in patient populations, relatively minor adjustments to the currently available mAb

products can counter these changes. Additionally, the FDA has issued guidance encouraging use of

existing formulations, platforms, and clinical protocols to facilitate expedited review and rapid

introduction of these modified mAb products to general public [32].

In summary, we demonstrated that mAb treatment with bamlanivimab was associated with an

approximately 80% reduction in the risk of medical visits among a diverse COVID-19 patient population

under real-world conditions. Increasing availability and utilization of novel COVID-19 therapeutics may

improve patient outcomes, reduce burden on the health system, and contribute to increased health equity

in the United States.

FUNDING AND CONFLICT OF INTEREST STATEMENT

an interest in the submitted work in the previous three years; no other relationships or activities that could

appear to have influenced the submitted work.

ACKNOWLEDGEMENTS

The authors acknowledge the significant efforts of George (Mark) Thorp, RN, EMT-P, who led and

coordinated the Disaster Medical Assistance Team's mAb infusion site set-up, initiation, and integration

with the Tucson Medical Center. The authors thank David W. Forest, Christopher Florko, and Judy

McCord from TMC Health Care, who provided extensive time and support for this analysis.

REFERENCES

266   1.   ProMed-mail. Undiagnosed pneumonia - China (Hubei) Request for Information. 2019. Available

267   at: http://www.promedmail.org. Accessed 1 February 2021.

268   2.   Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease

269   2019 (COVID-19) Outbreak in China. JAMA **2020**; 323:1239. Available at:

270   https://jamanetwork.com/journals/jama/fullarticle/2762130.

271   3.   Yanes-Lane M, Winters N, Fregonese F, et al. Proportion of asymptomatic infection among

272   COVID-19 positive persons and their transmission potential: A systematic review and meta-

273   analysis. PLoS One **2020**; 15:e0241536. Available at:

274   https://dx.plos.org/10.1371/journal.pone.0241536.

275   4.   Ou M, Zhu J, Ji P, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol

276   Infect **2020**; 148:e175. Available at:

277   https://www.cambridge.org/core/product/identifier/S095026882000179X/type/journal_article.

278   5.   Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019

279   (COVID-19) infection. Int Urol Nephrol **2020**; 52:1193–1194. Available at:

280   http://link.springer.com/10.1007/s11255-020-02451-9.

281   6.   Oetjens MT, Luo JZ, Chang A, et al. Electronic health record analysis identifies kidney disease as

282   the leading risk factor for hospitalization in confirmed COVID-19 patients. PLoS One **2020**;

283   15:e0242182. Available at: https://dx.plos.org/10.1371/journal.pone.0242182.

284   7.   Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for COVID-19–Related

285   Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death —

286   United States, March–December 2020. MMWR Morb Mortal Wkly Rep **2021**; 70:355–361.

287   Available at: http://www.cdc.gov/mmwr/volumes/70/wr/mm7010e4.htm?s_cid=mm7010e4_w.

288   8.   U.S. Interagency Data Strategy and Execution Working Group. Community Profile Reports. 2021.

289   Available at: https://beta.healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-

290   d9w9. Accessed 14 March 2021.

291   9.   U.S. Department of Health and Human Services. COVID-19 Reported Patient Impact and Hospital

292   Capacity by State Timeseries. 2021. Available at: https://healthdata.gov/Hospital/COVID-19-

293   Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh. Accessed 1 February 2021.

294   10.   Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients

295   with Covid-19. N Engl J Med **2021**; 384:229–237. Available at:

296   http://www.nejm.org/doi/10.1056/NEJMoa2029849.

297   11.   Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination

298   With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19. JAMA **2021**;

299   325:632. Available at: https://jamanetwork.com/journals/jama/fullarticle/2775647.

300   12.   Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody

301   Cocktail, in Outpatients with Covid-19. N Engl J Med **2021**; 384:238–251. Available at:

302   http://www.nejm.org/doi/10.1056/NEJMoa2035002.

303   13.   The National Academies of Sciences Engineering and Medicine. Rapid Expert Consultation on

304   Allocating COVID-19 Monoclonal Antibody Therapies and Other Novel Therapeutics (January

305   29, 2021). Washington, D.C.: National Academies Press, 2021. Available at:

306   https://www.nap.edu/catalog/26063.

307   14.   Lopez L, Hart LH, Katz MH. Racial and Ethnic Health Disparities Related to COVID-19. JAMA

308   **2021**; 325:719. Available at: https://jamanetwork.com/journals/jama/fullarticle/2775687.

309   15.   Lambrou A, Stewart M, Rainwater-Lovett K, et al. Implementation of SARS-CoV-2 monoclonal

310   antibody infusion sites at three medical centers in the United States: Strengths and challenges to

311   inform COVID-19 pandemic and future public health emergency use. (Manuscript In Progress)

312   **2021**

313   16.   Data USA. Tucson, AZ. 2018. Available at: https://datausa.io/profile/geo/tucson-az/. Accessed 21

314   March 2021.

315   17.   U.S. Census Bureau. Income and Poverty in the United States: 2019. 2020. Available at:

316   https://www.census.gov/library/publications/2020/demo/p60-270.html.

18. U.S. Department of Health and Human Services. Research Guidance on Coronavirus. 2020.

Available at: https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-guidance-on-covid-

19/index.html. Accessed 7 January 2021.

19. Ewing A, Lee EC, Viboud C, Bansal S. Contact, travel, and transmission: The impact of winter

holidays on influenza dynamics in the United States. J Infect Dis **2016**; :jiw642. Available at:

https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiw642.

20. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict

potential COVID-19. Nat Med **2020**; 26:1037–1040. Available at:

http://www.nature.com/articles/s41591-020-0916-2.

21. Clifford CT, Pour TR, Freeman R, et al. Association between COVID-19 diagnosis and presenting

chief complaint from New York City triage data. Am J Emerg Med **2020**; Available at:

https://linkinghub.elsevier.com/retrieve/pii/S0735675720309864.

22. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in

primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev

2020; Available at: http://doi.wiley.com/10.1002/14651858.CD013665.

23. Perotte R, Sugalski G, Underwood JP, Ullo M. Characterizing COVID-19: A chief complaint

based approach. Am J Emerg Med **2020**; Available at:

https://linkinghub.elsevier.com/retrieve/pii/S0735675720308135.

24. R Core Team. R: A language and environment for statistical computing. 2017; Available at:

https://www.r-project.org/.

25. U.S. Department of Health and Human Services. Intensive Care Unit Bed Utilization by State.

2021. Available at: https://protect-public.hhs.gov/pages/hospital-utilization. Accessed 14 March

2021.

26. Wang EC-H, Wright A. Characterizing outpatient problem list completeness and duplications in

the electronic health record. J Am Med Informatics Assoc **2020**; 27:1190–1197. Available at:

https://academic.oup.com/jamia/article/27/8/1190/5867232.

27.   Weiskopf NG, Rusanov A, Weng C. Sick patients have more data: the non-random completeness

344   of electronic health records. AMIA . Annu Symp proceedings AMIA Symp **2013**; 2013:1472–7.

345   Available at: http://www.ncbi.nlm.nih.gov/pubmed/24551421.

346   28.   Kaiser Family Foundation. COVID-19 Vaccine Hesitancy: Trends, Reasons, and Subgroups. 2020.

347   Available at: https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-

348   december-2020/. Accessed 15 March 2021.

349   29.   Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 Vaccination Intent, Perceptions, and

350   Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States,

351   September and December 2020. MMWR Morb Mortal Wkly Rep **2021**; 70:217–222. Available at:

352   http://www.cdc.gov/mmwr/volumes/70/wr/mm7006e3.htm?s_cid=mm7006e3_w.

353   30.   Wang P, Nair MS, Liu L, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and

354   B.1.1.7. Nature **2021**; Available at: http://www.nature.com/articles/s41586-021-03398-2.

355   31.   Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by

356   monoclonal and serum-derived polyclonal antibodies. Nat Med **2021**; Available at:

357   http://www.nature.com/articles/s41591-021-01294-w.

358   32.   US Department of Health and Human Services Food and Drug Administration Center for Drug

359   Evaluation and Research. Development of Monoclonal Antibody Products Targeting SARS-CoV-

360   2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health

361   Emergency: Guidance for Industry. 2021. Available at: https://www.fda.gov/regulatory-

362   information/search-fda-guidance-documents/development-monoclonal-antibody-products-

363   targeting-sars-cov-2-including-addressing-impact-emerging. Accessed 17 March 2021.

364   33.   U.S. Centers for Disease Control and Prevention National Center for Health Statistics. Clinical

365   Growth Charts. 2017. Available at: https://www.cdc.gov/growthcharts/clinical_charts.htm.

366   Accessed 1 February 2021.

368   **FIGURES AND TABLES**

369   **Figure 1**. Flow diagram applying the inclusion criteria to collected health records that generated the final

370   study population.

372   **Table 1.** Eligibility criteria for SARS-CoV-2 monoclonal antibody infusions.

Inclusion Criteria

Laboratory-confirmed COVID-19 (documented positive COVID-19 viral test result)
Symptom onset within the last ten days
≥12 years of age and weight ≥40 kilograms
Plus, at least ONE of the following risk factors:

- Body mass index ≥ 35
- Chronic kidney disease
- Diabetes mellitus
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- ≥ 65 years of age
- ≥ 55 years of age AND:
  - Cardiovascular disease, or
  - Hypertension, or
  - Chronic pulmonary obstructive disease/other chronic respiratory disease

- 12 – 17 years of age AND:
  - BMI ≥ 85th percentile for age and gender based on Centers for Disease Control and Prevention's growth charts[33], or
  - Sickle cell disease, or
  - Congenital or acquired heart disease, or
  - Neurodevelopmental disorders (e.g., cerebral palsy), or
  - A medically-related technological dependence (e.g., tracheostomy, gastrostomy, positive pressure ventilation unrelated to COVID-19), or
  - Asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control.

374 **Table 2.** Baseline demographic and medical characteristics of SARS-CoV-2-positive patients.

375 Abbreviations: Max, maximum; Min, minimum; SD, standard deviation.

	Untreated (N=328)	mAB Treated (N=270)	Overall (N=598)	P-value
Sex				0.10
Female	211 (64.3%)	155 (57.4%)	366 (61.2%)	
Male	117 (35.7%)	115 (42.6%)	232 (38.8%)	
Age				0.03
Mean (SD)	61.0 (17.8)	63.9 (15.9)	62.3 (17.0)	
Median [Min, Max]	65.0 [13.0, 98.0]	66.0 [18.0, 98.0]	65.0 [13.0, 98.0]	
Age greater than 65				0.33
Yes	168 (51.2%)	150 (55.6%)	318 (53.2%)	
No	160 (48.8%)	120 (44.4%)	280 (46.8%)	
Race				0.66
American Indian, Alaskan Native	5 (1.5%)	6 (2.2%)	11 (1.8%)	
Asian	5 (1.5%)	4 (1.5%)	9 (1.5%)	
Black	14 (4.3%)	5 (1.9%)	19 (3.2%)	
Hawaiian, Pacific Islander	1 (0.3%)	1 (0.4%)	2 (0.3%)	
Other	11 (3.4%)	6 (2.2%)	17 (2.8%)	
White	278 (84.8%)	214 (79.3%)	492 (82.3%)	
Missing	14 (4.3%)	34 (12.6%)	48 (8.0%)	
Ethnicity				0.58
Hispanic	129 (39.3%)	102 (37.8%)	231 (38.6%)	
Non-Hispanic	188 (57.3%)	133 (49.3%)	321 (53.7%)	
Missing	11 (3.4%)	35 (13.0%)	46 (7.7%)	
BMI				<0.01
30 or greater	52 (15.9%)	24 (8.9%)	76 (12.7%)	
35 or greater	35 (10.7%)	11 (4.1%)	46 (7.7%)	
Hypertension				<0.01
Yes	176 (53.7%)	55 (20.4%)	231 (38.6%)	
No	152 (46.3%)	215 (79.6%)	367 (61.4%)	
Chronic Kidney Disease				0.22
Yes	19 (5.8%)	9 (3.3%)	28 (4.7%)	
No	309 (94.2%)	261 (96.7%)	570 (95.3%)	
Cardiovascular Disease				<0.01
Yes	71 (21.6%)	20 (7.4%)	91 (15.2%)	
No	257 (78.4%)	250 (92.6%)	507 (84.8%)	
Admission				<0.01
Yes	39 (11.9%)	5 (1.9%)	44 (7.4%)	
No	289 (88.1%)	265 (98.1%)	554 (92.6%)	

Table 3. Risk of COVID-19-related hospitalization or emergency department visit within 30 days of SARS-CoV-2-positive viral test. *p<0.05. Abbreviations: CI, confidence interval; mAb, monoclonal antibody; OR, odds ratio.

	Unadjusted		Adjusted	
	OR	[95% CI]	OR	[95% CI]
(Intercept)			0.05	[0.02, 0.12]
Gender				
Female	1.00	[0.54, 1.93]	0.88	[0.44, 1.78]
Male	*Reference*		*Reference*	
Age (years)				
≤64	*Reference*		*Reference*	
>65	1.06	[0.57, 1.99]	2.10	[0.97, 4.77]
Race				
Black	1.60	[0.23, 5.90]	1.2	[0.17, 5.12]
White	*Reference*		*Reference*	
Other	0.36	[0.02, 1.71]	0.35	[0.02, 1.79]
Unknown	0.29	[0.01, 1.35]	0.54	[0.03, 2.87]
Ethnicity				
Hispanic	1.50	[0.80, 2.78]	1.66	[0.84, 3.32]
Non-Hispanic	*Reference*		*Reference*	
Body Mass Index				
<30	*Reference*		*Reference*	
≥30 and <35	1.61	[0.67, 3.46]	1.98	[0.76, 4.76]
≥35	4.95	[2.21, 10.5]*	6.44	[2.48, 16.71]*
Comorbidities				
Hypertension	2.22	[1.19, 4.19]*	1.37	[0.67, 2.81]
Chronic Kidney Disease	1.61	[0.36, 4.89]	1.15	[0.25, 3.79]
Cardiovascular Disease	1.73	[0.78, 3.54]	1.07	[0.45, 2.40]
mAb Treatment	0.14	[0.05, 0.34]*	0.18	[0.06, 0.44]*

 Supplemental Table. STROBE Statement

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract, (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Pg 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Pgs 4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg 5
Methods			
Study design	4	Present key elements of study design early in the paper	Pgs 5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pgs 5-6
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (*b*) For matched studies, give matching criteria and number of exposed and unexposed	Pg 6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pgs 6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pgs 6-7
Bias	9	Describe any efforts to address potential sources of bias	Pg 6
Study size	10	Explain how the study size was arrived at	Pgs 6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Pgs 7-8
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding (*b*) Describe any methods used to examine subgroups and interactions (*c*) Explain how missing data were addressed (*d*) If applicable, explain how loss to follow-up was addressed (*e*) Describe any sensitivity analyses	Pg 8
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Pg 8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	Pg 8
Outcome data	15*	Report numbers of outcome events or summary measures over time	Pg 9

Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (*b*) Report category boundaries when continuous variables were categorized (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Pg 9
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A

Discussion

Key results	18	Summarise key results with reference to study objectives	Pgs 9-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg 11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pgs 9, 12

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg 12